2014•The Lancet OncologyRequires access

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Kirit M. Ardeshna, Wendi Qian, Paul Smith, Nivette Braganca, Lisa Lowry, Pip Patrick, June Warden, Lindsey Stevens, Christopher Pocock, Fiona Miall, David Cunningham, John Davies, Andrew Jack, Richard Stephens, Jan Walewski, Burhan Ferhanoğlu, Ken Bradstock, David C. Linch

Open publisher page 393 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 393 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Rituximab, Medicine, Watchful waiting, Follicular lymphoma, Asymptomatic, Maintenance therapy, Internal medicine, Surgery